StreetInsider.com News Articles

AtriCure Inc. (ATRC) PT Raised to $68 at Citizens on Upside to Current Forecasts

Wed, 21 Oct 2026 05:24:23 -0400

Citizens analyst Daniel Stauder raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $68.00 (from $52.00) while maintaining a Market Outperform rating.

The analyst commented, "We reiterate our Market Outperform rating and raise our price target to $68 from $52 on shares of AtriCure (ATRC) after updating our model and introducing our FY28 estimates...AtriCure has traded up ~45% YTD and has more than doubled since mid-2026 (closed at ~$28 on 6/30/26). In our view, the recent acceleration in the name likely stems from investors better appreciating the opportunities the company's clinical and product pipeline could generate as early as 2028

AtriCure Inc. (ATRC) PT Raised to $68 at Citizens on Upside to Current Forecasts

Wed, 21 Oct 2026 05:24:23 -0400

Citizens analyst Daniel Stauder raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $68.00 (from $52.00) while maintaining a Market Outperform rating.

AtriCure to Announce Third Quarter 2026 Financial Results

Tue, 13 Oct 2026 08:00:00 -0400

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss its third quarter financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to

AtriCure to Announce Third Quarter 2026 Financial Results

Tue, 13 Oct 2026 08:00:00 -0400

Form SCHEDULE 13G/A AtriCure, Inc. Filed by: BlackRock, Inc.

Mon, 05 Oct 2026 11:59:00 -0400

si-local-file:///var/storage/secattach/20261005/27147630.html

Freedom Capital Downgrades AtriCure Inc. (ATRC) to Hold

Fri, 02 Oct 2026 06:12:11 -0400

Freedom Capital analyst Keith Hinton downgraded AtriCure Inc. (NASDAQ: ATRC) from Buy to Hold with a price target of $57.00 (from $43.00).

The analyst comments "We are downgrading ATRC to a HOLD, though we raise our price target to $57 (from $43) based on ~25x 2027E EBITDA. We expect BoX-NoAF POAF data (inhouse in 1Q27, public in 2Q27) to be positive, though we think prior supportive data comes with notable caveats, potentially leaving less margin for error than headline numbers suggest. If positive, a POAF label should be a meaningful sales and margin catalyst in 2028+, but with ATRC shares ~2x

Freedom Capital Downgrades AtriCure Inc. (ATRC) to Hold

Fri, 02 Oct 2026 06:12:11 -0400

Freedom Capital analyst Keith Hinton downgraded AtriCure Inc. (NASDAQ: ATRC) from Buy to Hold with a price target of $57.00 (from $43.00).

Form 4 AtriCure, Inc. For: Sep 23 Filed by: Privitera Salvatore

Thu, 24 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260924/27102825.html

Form 144 AtriCure, Inc. Filed by: Privitera Salvatore

Wed, 23 Sep 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260923/27096709.html

AtriCure Inc. (ATRC) PT Raised to $65 by Stifel - Physicians Favor LAAM Technology

Thu, 17 Sep 2026 07:43:30 -0400

Stifel analyst John McAulay reiterated a Buy rating and $65.00 price target on AtriCure Inc. (NASDAQ: ATRC).

The analyst commented, "Since the company’s March 2025 investor day, AtriCure has delivered above the revenue and profitability expectations set out, completed enrollment in LeAAPS, and continued to enroll BoxX No-AF, both TAM-expanding clinical trials. Along with these trials, earlier this year, the Society of Thoracic Surgeons (STS) announced a quality metric, emphasizing that afib must be addressed in cardiac surgery patients, which could be implemented over the next several years. To better understand how these trials and the afib quality metric could impact

Form 4 AtriCure, Inc. For: Sep 11 Filed by: GROVES REGINA E

Mon, 14 Sep 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260914/27059535.html

Form 144 AtriCure, Inc. Filed by: GROVES REGINA E

Fri, 11 Sep 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260911/27051626.html

Form 4 AtriCure, Inc. For: Sep 08 Filed by: Privitera Salvatore

Thu, 10 Sep 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260910/27046316.html

AtriCure Inc. (ATRC) PT Raised to $64 at Needham

Wed, 02 Sep 2026 07:16:57 -0400

(Updated - September 2, 2026 7:16 AM EDT)

Needham analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $64.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: 'ATRC's BoxX-NoAF randomized controlled trial (RCT) is evaluating whether concomitant use of ATRC's EnCompass and AtriClip (known as the BoxX procedure) in cardiac surgery can reduce the rate of post-operative atrial fibrillation (POAF) at 30 days and improve long-term freedom from AF at three years. The trial is expected to be fully enrolled by the end of 2026 and 30-day data should be released in 1H27. A meta-analysis of

AtriCure Inc. (ATRC) PT Raised to $64 at Needham

Wed, 02 Sep 2026 07:16:57 -0400

(Updated - September 2, 2026 7:16 AM EDT)

Needham analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $64.00 (from $45.00) while maintaining a Buy rating.

AtriCure Inc. (ATRC) PT Raised to $60 at Piper Sandler

Thu, 27 Aug 2026 09:08:42 -0400

(Updated - August 27, 2026 9:08 AM EDT)

Piper Sandler analyst Matt O'Brien raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $60.00 (from $50.00) while maintaining a Overweight rating.

The analyst commented: "STS Quality Measure An Underappreciated Near-Term Catalyst; Earlier this year, STS introduced a new quality measure focused on pre-operative AF treatment during cardiac surgery, which we believe represents an underappreciated catalyst for AtriCure’s open ablation business. Despite clinical guideline recommendations, adoption remains underpenetrated. Our assessment of historical quality measure adoption suggests that AtriCure’s penetration of this ~$470M domestic market could increase from 31% today to 45% by the

AtriCure Inc. (ATRC) PT Raised to $60 at Piper Sandler

Thu, 27 Aug 2026 09:08:42 -0400

(Updated - August 27, 2026 9:08 AM EDT)

Piper Sandler analyst Matt O'Brien raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $60.00 (from $50.00) while maintaining a Overweight rating.

Form 4 AtriCure, Inc. For: Aug 24 Filed by: Dahlquist Karl S.

Wed, 26 Aug 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260826/26977090.html

Form 4 AtriCure, Inc. For: Aug 24 Filed by: Dahlquist Karl S.

Wed, 26 Aug 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260826/26977090.html

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

Tue, 25 Aug 2026 08:00:00 -0400

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.

AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure,

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

Tue, 25 Aug 2026 08:00:00 -0400

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.

About AtriCure

AtriCure,

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

Tue, 25 Aug 2026 08:00:00 -0400

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.

About AtriCure

AtriCure,

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

Tue, 25 Aug 2026 08:00:00 -0400

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.

About AtriCure

AtriCure,

Form 144 AtriCure, Inc. Filed by: Dahlquist Karl S.

Mon, 24 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260824/26968210.html

Form 144 AtriCure, Inc. Filed by: Dahlquist Karl S.

Mon, 24 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260824/26968210.html